查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553415

病毒惰性市場規模、佔有率、趨勢分析報告：按產品和服務、按應用、按最終用途、按地區、按細分市場、預測，2024-2030 年

Viral Inactivation Market Size, Share & Trends Analysis Report By Products & Services (Kits & Reagents), By Application (Vaccines & Therapeutics), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

病毒惰性市場成長與趨勢

Grand View Research, Inc.最新報告顯示，到2030年，全球病毒惰性市場規模預計將達到13.716億美元，預測期內複合年成長率為11.4%。

主要成長動力包括製藥和生物製藥公司數量的增加、FDA 藥品批准量的增加、生命科學產業的成長以及政府對新療法和藥物開發的資助增加。

由於公司數量的穩定增加、新藥的推出和新藥的發現，製藥和生物製藥行業正在經歷顯著的成長。隨著世界範圍內疾病數量的增加，世界各地對新藥和改進治療方法的需求也在增加。主要企業加大研發投入，加上尋找治療疾病的新治療方法的需求，正在促進並加速製藥和生物製藥公司的巨大成長。

本公司開發新藥以增加健康益處。世界各地人們生活方式的改變和久坐生活方式的建立是導致需要藥物和治療方法治療的慢性疾病增加的主要原因。據 FDA 稱，2014 年核准了41 種核准，隔年批准了 45 種新藥。這也有助於成長。

近年來，大量資金投入製藥和生物技術產業。儘管私人公司為新藥和新治療方法的開發做出了重大貢獻，但政府在新治療方法研發上的支出也在增加。近年來，資金的增加也導致 FDA核准數量的增加。所有這些因素都促進了病毒惰性市場的巨大成長。

病毒去活化市場報告亮點

  • 由於消耗品使用增加，套件和試劑佔最大佔有率。
  • 疫苗和治療藥物在應用中佔據最大佔有率，並且由於生技藥品需求的增加預計將快速成長。
  • 由於全球製藥 CRO 的崛起，服務領域預計將以最快的速度成長。
  • 由於旨在遏制慢性病發病率的醫療改革以及主要企業和先進基礎設施的存在，北美佔據了最大的市場佔有率。
  • 由於醫療改革和製藥業開拓的市場機會，預計亞太地區將在預測期內繁榮發展。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 病毒去活化的變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 病毒去活化分析工具
    • 波特的分析
    • PESTEL分析

第4章病毒去活化市場：按產品和服務分類的估計和趨勢分析

  • 細分儀表板
  • 病毒去活化市場：2023年和2030年產品和服務的波動分析
  • 試劑套件和試劑
  • 系統及配件
  • 服務

第5章病毒去活化市場：按應用、估計和趨勢分析

  • 細分儀表板
  • 病毒去活化市場：2023 年和 2030 年應用變化分析
  • 疫苗和治療
  • 幹細胞產品
  • 血液和血液製品
  • 組織/組織產品
  • 細胞和基因治療

第6章 病毒去活化市場：依最終用途分類的估計與趨勢分析

  • 細分儀表板
  • 病毒去活化市場：2023 年和 2030 年最終用途變化分析
  • 製藥和生物技術公司
  • CRO
  • 學術研究所
  • 其他

第7章 病毒去活化市場：區域估計與趨勢分析

  • 2023 年和 2030 年按地區分類的病毒去活化佔有率，百萬美元
  • 北美洲
    • 北美病毒去活化估計與預測，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030 年歐洲病毒去活化估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030 年亞太地區病毒去活化估計與預測
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
  • 拉丁美洲
    • 2018-2030 年拉丁美洲病毒去活化估計與預測
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 2018-2030 年中東和非洲病毒去活化估計和預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Charles River Laboratories, Inc.
    • Clean Cells
    • Cytiva（Danaher Corporation）
    • Merck KGaA
    • Mettler Toledo
    • Parker Hannifin Corp
    • Rad Source Technologies Inc
    • Sartorius AG
    • Texcell SA
    • Vironova AB
簡介目錄
Product Code: GVR-1-68038-998-2

Viral Inactivation Market Growth & Trends:

The global viral inactivation market size is expected to reach USD 1,371.6 million by 2030, registering a CAGR of 11.4% during the forecast period, according to a new report by Grand View Research, Inc. Rise in the number of pharmaceutical and biopharmaceutical companies, increase in FDA drug approvals, growth of the life sciences industry, increase in government funding for novel therapies, and drug development are some of the major factors contributing to the growth.

Immense growth has been witnessed in the pharmaceutical and biopharmaceutical industry with a steady rise in the number of companies, drug launches, and new drug discoveries. With an increase in the number of diseases worldwide, the need for new & improved drugs and therapies has been witnessed on a global front. Increase in investment by top players in research and development coupled with the need to find new therapies for the treatment of diseases has contributed to immense growth of pharmaceutical and biopharmaceutical companies, thereby accelerating growth.

Newer drugs are being developed by companies to offer incremental health benefits. Changing lifestyle of people across the globe and adoption of sedentary living habits are primary reasons responsible for the increase in the number of chronic diseases that require drugs and therapies for treatment. According to the FDA, in the year 2014, 41 novel drugs were approved and 45 in the consequent year. This has also been contributing to growth.

Immense funding has been witnessed in the pharmaceutical and biotechnology industries in the recent years. It has been observed that private players are the major contributors for the development of new drugs and therapies, however, there has been increasing government spending on the research and development of new therapies. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. All these factors have been contributing to the immense growth of the viral inactivation market.

Viral Inactivation Market Report Highlights:

  • Kits and reagents held the largest share owing to increasing usage of consumables
  • Vaccines and therapeutics held the largest share, on the basis of application, and is expected to be the fastest growing segment due to the increased demand for biologics
  • The services segment is anticipated to grow at the fastest rate due to increase in the number of pharmaceutical CROs globally
  • North America accounted for the largest share owing to presence of dominant players and availability of sophisticated infrastructure along with healthcare reforms to curb the incidence of chronic diseases
  • The Asia Pacific region is expected to flourish during the forecast period owing to healthcare reforms and untapped market opportunities in the pharmaceutical industry

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Viral Inactivation Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Viral Inactivation Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Viral Inactivation Market: Product & Services Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Viral Inactivation Market: Product & services Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Kits & Reagents
    • 4.3.1. Kits & Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Systems & Accessories
    • 4.4.1. Systems & Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Viral Inactivation Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Viral Inactivation Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Vaccines & Therapeutics
    • 5.3.1. Vaccines & Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Stem Cell Products
    • 5.4.1. Stem Cell Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Blood & Blood Products
    • 5.5.1. Blood & Blood Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Tissue/ Tissue Products
    • 5.6.1. Tissue/ Tissue Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Cellular and Gene Therapy
    • 5.7.1. Cellular and Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Viral Inactivation Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Viral Inactivation Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Pharmaceutical & Biotechnological Companies
    • 6.3.1. Pharmaceutical & Biotechnological Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. CROs
    • 6.4.1. CROs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Academic and Research Institutes
    • 6.5.1. Academic and Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Viral Inactivation Market: Regional Estimates & Trend Analysis

  • 7.1. Viral Inactivation Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Sweden Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Viral Inactivation and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Charles River Laboratories, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Clean Cells
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Cytiva (Danaher Corporation)
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Merck KGaA
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Mettler Toledo
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Parker Hannifin Corp
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Rad Source Technologies Inc
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Sartorius AG
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Texcell SA
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Vironova AB
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives